LUNG (pulmonx.com) Wutah bathi resik saben saham ing taun iki

Logistics disruptions and sanctions are limiting the distribution of Pulmonx Corporation (LUNG) systems in several countries. Against this backdrop, annual EPS progress exhibits volatility, with the 27.20 mark serving as a key metric. Pulmonx Corporation (LUNG) leads emphysema therapy via the Zephyr system, and its current strategic vector is focused on rapidly increasing the number of specialized clinics in the US.
Rincian metrik keuangan lan pasar Pulmonx Corporation (LUNG)

This indicator assesses the year-over-year dynamics of net earnings per share. The proportional growth of EPS compared to last year visualizes capital generation efficiency and the speed of business scaling. The metric calculates the percentage deviation of current income from the same period last year, identifying margin compression or expansion. Negative trends signal a decline in profitability. For Pulmonx Corporation (LUNG), strong pricing power in the Zephyr valve market should support a positive trajectory for this metric.